Regado Snags $51M From Venture Funding Led By Rusnano
This article was originally published in The Pink Sheet Daily
Executive Summary
New Jersey biotech Regado Biosciences raised $51 million in a Series E offering led by Russian investment group Rusnano. The money will be used to initiate a Phase III trial of its anticoagulant REG1.